Trial Search Results

A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

The main purpose of this research study is to learn if Inotuzumab Ozogamicin is a more effective treatment when compared to chemotherapies commonly used in patients with relapsed or refractory Acute Lymphoblastic Leukemia (ALL). Also, what the side effects are associated to inotuzumab ozogamicin treatment and how it distributes through the body will be assessed.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Pfizer

Collaborator: UCB Pharma

Stanford Investigator(s):

Intervention(s):

  • Drug: inotuzumab ozogamicin
  • Drug: FLAG (fludarabine, cytarabine and G-CSF)
  • Drug: HIDAC (high dose cytarabine)
  • Drug: cytarabine and mitoxantrone

Phase:

Phase 3

Eligibility


Inclusion Criteria:

   - CD22 expression

   - Adequate liver and renal functions

Exclusion Criteria:

   - Isolated extramedullary disease

   - Active Central Nervous System [CNS] disease

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting